Established Paradigm

Paris - Combination immunotherapy for psoriasis is coming into the clinic. Experience is showing it can be a valuable strategy for increasing efficacy while minimizing toxicity, both acutely and potentially over the longer term, Christopher E.M. Griffiths, M.D., said at the World Congress of Dermatology.

Related Videos
Related Content

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Highlights from AAD 2023

March 23rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Technology Could Allow Us to Rethink Alopecia Scores

March 23rd 2023

Upadacitinib Advances to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.